ALK and non-small cell lung carcinoma: Experimental procedures in the GEMSTONE-301 have been modified based on the PACIFIC trial (14), which not only recruits unresectable stage III NSCLC patients with more actual conditions for sequential radiotherapy and chemotherapy, but also excludes patients with EGFR/ALK/ROS1 mutations who are highly detected in East Asian populations and not well responsive to immunotherapy.